Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

Journal of the National Cancer Institute - 1 Sept 2014

Wang Zhiyong, Martin Daniel, Molinolo Alfredo A, Patel Vyomesh, Iglesias-Bartolome Ramiro, Degese Maria Sol, Vitale-Cross Lynn, Chen Qianming, Gutkind J Silvio

Abstract excerpt

BACKGROUND: Cetuximab, a monoclonal blocking antibody against the epidermal growth factor receptor EGFR, has been approved for the treatment of squamous cell carcinomas of the head and neck (HNSCC). However, only few patients display long-term responses, prompting the search for cetuximab resistance mechanisms and new therapeutic options enhancing cetuximab effectiveness. METHODS: Cetuximab-sensitive HNSCC cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Class I Phosphatidylinositol 3-Kinases

Share to Head and Neck Neoplasms

Share to Lymphangiogenesis

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 25099740
DOI: 10.1093/jnci/dju215
PMCID: PMC4133928

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.PMID 25099740Read ↗

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell CarcinomasSemantic proximity Read ↗

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.Semantic proximity Read ↗

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.Semantic proximity Read ↗

The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Semantic proximity Read ↗

Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck CancerSemantic proximity Read ↗

CAV2 Confers Cetuximab Resistance in HNSCC by Ubiquitin-Mediated Disruption of the PACT-PKR Tumor Suppressor AxisSemantic proximity Read ↗

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signalingSemantic proximity Read ↗

A 3D Bioprinted Spheroid Model of Nasopharyngeal Carcinoma Uncovers Constitutive IGF‑1R/PI3K/AKT Signaling as a Mediator of Intrinsic Cetuximab Resistance and a Therapeutic VulnerabilitySemantic proximity Read ↗

Is biomarker research advancing in the era of personalized medicine for head and neck cancer?Semantic proximity Read ↗

Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.Semantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.